DS
Dhanalaxmi Sadula
About Dhanalaxmi Sadula
Data last updated:
Dhanalaxmi Sadula is a Director at Primero Life Sciences Private Limited (since 2022) and Designated Partner at Spindrift Pharma Llp (since 2023). The companies operate in Trading and Paper. The largest current company by reported revenue is Primero Life Sciences Private Limited at ₹1.06 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Primero Life Sciences Private Limited U51909TG2022PTC165249 | Director | 28 Jul 2022 | 2022 | ₹1.06 Cr (FY 2025) | Active |
| Spindrift Pharma Llp ABZ-9980 | Designated Partner | 06 Feb 2023 | 2023 | Active |
Board colleagues of Dhanalaxmi Sadula
| Name | DIN | Company | Designation |
|---|---|---|---|
| Damodar Sadula | 09689511 | Primero Life Sciences Private Limited | Director |
| Sumankumar Sadula | 09689510 | Primero Life Sciences Private Limited , Spindrift Pharma Llp | Managing Director |
| Naresh Palem | 10043338 | Spindrift Pharma Llp | Designated Partner |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Dhanalaxmi Sadula
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dhanalaxmi Sadula
Dhanalaxmi Sadula currently holds 2 directorships: Primero Life Sciences Private Limited (Director, since 28 Jul 2022, revenue ₹1.06 Cr (FY 2025)); Spindrift Pharma Llp (Designated Partner, since 06 Feb 2023).
Dhanalaxmi Sadula was first appointed on 28 Jul 2022 as Director at Primero Life Sciences Private Limited. The most recent appointment on record is 06 Feb 2023 at Spindrift Pharma Llp.
The current boards of Dhanalaxmi Sadula's companies include Damodar Sadula (Primero Life Sciences Private Limited), Sumankumar Sadula (Primero Life Sciences Private Limited), Naresh Palem (Spindrift Pharma Llp).